Phase 1a Open-label Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B in Healthy Malaria-Naive Adults Phase 1b Controlled Double Blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B
Latest Information Update: 28 Jun 2023
At a glance
- Drugs FMP010 vaccine (Primary) ; AS01B
- Indications Falciparum malaria
- Focus Adverse reactions
- 22 Mar 2012 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
- 22 Mar 2012 Official title amended as reported by ClinicalTrials.gov.
- 02 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.